The contributions of different enzymes to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) biotransformation were assessed in human lung microsomes prepared from peripheral lung specimens obtained from seven subjects. Metabolite formation was expressed as a percentage of total recovered radioactivity from 
Tobacco-specific nitrosamines represent one of the major classes of chemical carcinogens found in cigarette smoke, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK 1 ) is the most potent cancercausing tobacco-specific nitrosamine in all animal species tested (Hecht, 1998) . NNK and its keto-reduced major metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) require metabolic activation via ␣-carbon hydroxylation to form unstable intermediates that spontaneously decompose to produce alkylating agents. Reaction of these alkylating metabolites with DNA is believed to initiate carcinogenicity (Hecht, 1998) (Fig. 1) . Pyridine N-oxidation of NNK and NNAL results in formation of excretable N-oxides, which are detoxication products (Hecht, 1998) (Fig. 1) .
In rodents, cytochrome P450 (P450) enzymes play the major role in pulmonary NNK bioactivation (reviewed in Hecht, 1998) . The situation in human lung is more complex, with much lower levels of NNK bioactivation compared with rodents, and evidence implicating multiple enzyme systems including P450s, lipoxygenases (LOXs), prostaglandin H synthases (PHSs), and other peroxidases (Smith et al., 1992 (Smith et al., , 1999 .
Our previous observation of inhibition of NNK bioactivation by SKF-525A in human lung cells (Smith et al., 1999) , coupled with evidence of the abilities of various recombinant human P450s to catalyze NNK bioactivation (Hecht, 1998; Kushida et al., 2000; Su et al., 2000) , implicated cytochrome P450 in pulmonary NNK metabolism. Previous studies have demonstrated P450-catalyzed NNK bioactivation in human whole lung microsomes. However, information about roles of specific P450 enzymes was based on results in lung microsomes from a single patient in one study (Smith et al., 1992) and only three individuals in another . Our demonstration of considerable interindividual variability in NNK metabolism in lung cells (Smith et al., 1999) , and variable human lung metabolism of other carcinogens (Harris et al., 1976; De Flora et al., 1987) , indicated that valid conclusions regarding roles of different biotransformation enzymes required further examination.
The objective of the present study was to assess the contributions of various biotransformation enzymes pertinent to human pulmonary microsomal NNK metabolism using antibody and chemical inhibitors. P450 enzymes to be examined were selected based on previously demonstrated expression in human lung and by metabolic activity toward NNK in expression systems (reviewed in Hecht, 1998; and Su et al., 2000) . Thus, CYP2A6, CYP2A13, CYP3A4, CYP3A5, CYP2E1, and CYP2B6 were considered to be P450 enzymes most likely to be active in the human pulmonary biotransformation of NNK. Since our previous results suggested possible non-P450 contributions to NNK biotransformation in freshly isolated alveolar macrophages (Smith et al., 1999) , and PHS has been proposed as a potential NNK bioactivating enzyme Castonguay, 2000, 2001) , its involvement in human lung microsomal NNK metabolism was also assessed.
Materials and Methods
Chemicals. Chemicals were obtained as follows: [5- 3 H]NNK (2.1-4.2 Ci/mmol; Ͼ98% pure) from Chemsyn (Lenexa, KS); 1-aminobenzotriazole (ABT) from Color Your Enzyme (Kingston, ON, Canada); NNK, NNAL, 4-(methylnitrosamino)-1-(3-pyridyl-N-oxide)-1-butanone (NNK-N-oxide), 4-(methylnitrosamino)-1-(3-pyridyl-N-oxide)-1-butanol (NNAL-N-oxide), 4-hydroxy-1-(3-pyridyl)-1-butanone (keto alcohol), 1-(3-pyridyl)-1,4-butane diol (diol), 1-(3-pyridyl)-1-butanone-4-carboxylic acid (keto acid), 1-(3-pyridyl)-1-butanol-4-carboxylic acid (hydroxy acid), from Toronto Research Chemicals (North York, ON, Canada); Uniscint BD radioflow scintillation cocktail from National Diagnostics (Atlanta, GA); and EDTA, glucose 6-phosphate, glucose-6-phosphate dehydrogenase, indomethacin (INDO), 8-methoxypsoralen (8-MS), nordihydroguaiaretic acid (NDGA), orphenadrine hydrochloride (ORP), and troleandomycin (TAO), from Sigma-Aldrich (St. Louis, MO). Inhibitory monoclonal antibodies to human CYP2A6 (IH-MAB-2A6, for selective inhibition; Catalog No. A306), 3A4/5, 2E1, and 2B6 were purchased from BD Gentest (Woburn, MA.) . and N-benzyl-1-aminobenzotriazole (BBT) were synthesized as previously described (Mathews and Bend, 1986) . All other chemicals were reagent grade or better and were obtained from common commercial suppliers.
Tissue Procurement. Following informed consent, sections of peripheral human lung were obtained during clinically indicated lobectomy as described previously (Smith et al., 1999) . Tissue specimens were cut into 1.5-cm 3 pieces, wrapped in aluminum foil, frozen in liquid N 2 , and stored at Ϫ80°C until microsome preparation. Tissues were examined histologically for the presence of anomalies as described in (Smith et al., 1999) . Patients were characterized with respect to age, gender, surgical diagnosis, possible occupational exposure to carcinogens and/or biotransformation enzyme inducers/inhibitors, drug treatment 1 month before surgery, and self-reported smoking history. Patients were classed as former smokers if self-reported smoking history indicated cessation greater than 2 months before surgery. This time interval was chosen to eliminate the inductive effects of cigarette smoke on biotransformation enzymes (McLemore et al., 1990) .
Preparation of Human Whole Lung Microsomes. Tissue sections wrapped in foil were thawed on ice for 15 min. All subsequent manipulations were carried out on ice or at 4°C. The lung tissue was rinsed, chopped, and then homogenized using a Polytron homogenizer in 3 volumes of 0.1 M potassium phosphate buffer containing 1.15% KCl (pH 7.4). Microsomes were prepared by differential centrifugation (Donnelly et al., 1996) . Protein concentration was determined by the method of Lowry et al. (1951) , using bovine serum albumin as a standard.
FIG. 1. The proposed pathways of NNK metabolism.
Metabolites I and II are N-oxidation or detoxication metabolites; metabolites III through VI are endpoint metabolites of ␣-hydroxylation and are indicative of the formation of unstable reactive species (W, ૾, and ૺ); metabolite VII is the O-glucuronide of NNAL. Oxobutyl diazohydroxides (W) and hydroxybutyl diazohydroxides (૾) are proposed to form DNA adducts via pyridyloxobutylation and pyridylhydroxybutylation, respectively. Methyl diazohydroxides (ૺ) form DNA adducts via methylation.
Incubations with NNK. [5-
3 H]NNK was purified to Ͼ99.8% as described (Smith et al., 1999) before use. Incubation mixtures contained 0.1 M potassium phosphate buffer plus 1.15% KCl (pH 7.4), 4.2 M [5-
3 H]NNK, 1.0 mM EDTA, 3.0 mM MgCl 2 , and 1.0 mg microsomal protein in a total volume of 1.0 ml. The NADPH-generating system consisted of 5.0 mM glucose 6-phosphate, 2.0 units of glucose-6-phosphate dehydrogenase, and 1.25 mM NADP. The reaction mixture was incubated for 15 min at 37°C in a Dubnoff metabolic shaker. Reactions were terminated by addition of 300 l of 25% zinc sulfate and 300 l of saturated barium hydroxide. Samples were centrifuged at 2,500g for 5 min, and supernatants were frozen in liquid N 2 and stored at Ϫ80°C until analysis. Inhibitors were dissolved in methanol, which constituted 1.0% (v/v) of the total incubation volume; control incubations contained 1.0% methanol (v/v), which previously has been shown to have no appreciable effect on human lung microsomal NNK metabolism . Isozyme nonselective inhibitors of P450, SKF-525A (Ono et al., 1996) or ABT (Mathews et al., 1985) , were used to assess overall P450 contribution to NNK metabolism. 8-MS (for CYP2A6; Koenigs et al., 1997) and, potentially, CYP2A13 (Su et al., 2000) ; TAO (for CYP3A4/5; Newton et al., 1995) ; and ORP, ␣MB, or BBT (for CYP2B6; Mathews and Bend, 1986; Reidy et al., 1989) were used to assess contributions of specific P450 enzymes. PHS contributions were assessed using INDO (Smith and DeWitt, 1995) . Effects of NDGA, a LOX inhibitor (Van der Merwe et al., 1993) , were also assessed. For immunoinhibition studies, 1.0 mg of microsomal protein and 200 g of either anti-CYP2A6, CYP3A4/5, CYP2E1, or CYP2B6 supplied in 25 mM Tris buffer (pH 7.5) were incubated on ice for 20 min before use in incubations, as recommended by the supplier. Incubations in the absence of inhibitory antibodies also contained the Tris buffer supplied with the antibodies. All incubations were performed in duplicate, and components were preincubated for 15 min at 37°C to allow for the mechanism-based inhibitors to exert their effects before addition of [5- 3 H]NNK. Linearity of NNK metabolite formation by human lung microsomes has been demonstrated for at least 30 min (Smith et al., 1992) . For incubations with carbon monoxide (CO), mixtures were bubbled with CO for 1 min immediately before addition of [5- 3 H]NNK. Due to limitations in tissue availability, not all inhibitors could be tested in microsomes from all patients.
Assessment of NNK Biotransformation. Microsomal NNK biotransformation was analyzed as described (Smith et al., 1999) , except that 1.0 ml of the terminated, filtered reaction mixture was injected onto the high-performance liquid chromatography column, and radiometric quantitation of eluted products was accomplished with a ␤-ram radioactivity flow detector (IN/US Systems Inc., Tampa, FL) with Uniscint BD as the scintillation cocktail at a 3:1 cocktail/eluate flow mixture ratio. The metabolite reference standards solution contained NNK and each of the seven metabolites dissolved in methanol at 6.25 mM, of which 5.0 l were injected onto the column. NNK metabolite values from control incubates containing boiled microsomes were subtracted from each individual patient's microsomal metabolite profile. Microsomal incubations were analyzed in duplicate. For each NNK metabolite, the amount produced was expressed as a percentage of the total radioactivity recovered from [5-
3 H]NNK plus metabolites per milligram of protein per minute, to account for any differences in recovery of [5-3 H]NNK from incubate to incubate. Metabolite peaks were quantitated only if they were at least twice background radioactivity levels.
Data Analysis and Presentation. For microsomal NNK biotransformation, individual metabolite values represent the mean of duplicate incubations. When grouped, microsomal data are presented as means Ϯ S.D. Statistically significant differences in individual microsomal metabolite formation and differences following inhibitor treatments were determined by repeated measures analysis of variance (ANOVA) followed by the Tukey-Kramer test or Dunnett's multiple comparisons test, respectively. When Bartlett's test revealed heterogeneity of variance, a positive integer (k ϭ 1) was added to each datum because some points were equal to zero (nondetectable), and either log or reciprocal transformation was performed on the resultant values prior to conducting ANOVA (Zivin and Bartko, 1976) . If the transformed data did not achieve homogeneity of variance, the Freidman nonparametric repeated measures test was used (Zivin and Bartko, 1976) . P Ͻ 0.05 was considered statistically significant in all cases.
Results
Patient Demographics. Microsomes prepared from sections of peripheral lung obtained from seven human subjects (three males and four females) from eastern Ontario, aged 58.7 Ϯ 11.0 years, were used (Table 1) . Based on self-reported smoking histories, four individuals were current smokers, and three were former smokers. Although racial demographics were not obtained for all patients, the population in the catchment area for Kingston General Hospital is predominantly white.
[
5-3 H]NNK Biotransformation in Whole Lung Microsomes. Metabolism of [5-
3 H]NNK in human lung microsomes resulted in the formation of hydroxy acid, keto acid, diol, keto alcohol, NNAL-Noxide, NNK-N-oxide, and NNAL. NNAL was the major metabolite, and its formation ranged from 0.52 to 1.3%/mg of protein/min (representing ϳ 5-13 pmol of NNAL/mg of protein/min) (Fig. 2a) . Total bioactivation (sum of the four ␣-hydroxylation endpoint metabolites) ranged from 2.10 ϫ 10 Ϫ3 to 5.69 ϫ 10 Ϫ3 % ␣-hydroxylation/mg of protein/min, representing ϳ0.020 to 0.057 pmol ␣-hydroxylation/mg/ min, which was less than 1% of the initial amount of NNK over the 15-min incubation period (Fig. 2b) . Total N-oxidation (sum of NNAL-N-oxide and NNK-N-oxide) occurred at similar or slightly lower levels, with N-oxidation being nondetectable in microsomes from patient 5JM (Fig. 2c) . Keto acid and keto alcohol were detected in all of the patients' microsomal incubations, whereas five of seven formed detectable levels of hydroxy acid, and six of seven formed detectable levels of diol, NNAL-N-oxide, and NNK-N-oxide (data not shown). Frequency distribution histograms revealed the existence of high (6HM, 8HM, and 8JM) and low (3JM, 5JM, 7JM, and 9JM) NNK bioactivators, with significantly different mean total ␣-hydroxylation activities (i.e., 5.49 ϫ 10 Ϫ3 Ϯ 0.17 ϫ 10 Ϫ3 and 2.45 ϫ 10 Ϫ3 Ϯ 0.13 ϫ 10 Ϫ3 % ␣-hydroxylation/mg/min, respectively, P Ͻ 0.05, Student's t test) (Fig. 2b) . A similar trend for the same groups of patients was observed for total N-oxidation, but the difference fell just short of statistical significance (P ϭ 0.054) (Fig. 2c) . Individuals forming the highest amounts of NNAL did not consistently form the highest amounts of other metabolites (Fig. 2) .
When results from lung microsomes from different patients were grouped, formation of keto acid was higher than that of all other ␣-hydroxylation endpoint metabolites, and formation of keto alcohol was significantly higher than that of hydroxy acid, but not of diol (Fig.  3 ). This may have been due to higher levels of precursor for keto acid and keto alcohol (i.e., NNK) than of hydroxy acid and diol (i.e., NNAL).
There were no differences in total bioactivation or total N-oxidation in microsomes from current smokers (n ϭ 4) versus former smokers (n ϭ 3) (Student's t test, P Ͼ 0.05). Similarly, no differences were observed in formation of NNK metabolites between microsomes from male (n ϭ 4) and female (n ϭ 3) patients (P Ͼ 0.05, Student's t test).
Effects of Inhibitors on [5-3 H]NNK Biotransformation: Grouped Results. Most treatments had minimal effects on NNAL formation. However, the absence of an NADPH-generating system virtually abolished NNAL production, whereas incubations in the presence of 5.0 mM ABT formed significantly higher amounts of NNAL relative to control (Fig. 4a) . The absence of an NADPHgenerating system or the presence of 5.0 mM ABT greatly decreased total ␣-hydroxylation as well as total N-oxidation (Fig. 4, b and c) . This trend held for individual NNK metabolites with the exception of hydroxy acid and keto alcohol, where results where inconsistent (data not shown). There were no other statistically significant differences in incubations in the presence of either antibody or chemical inhibitors when results were grouped. However, a trend toward inhibition of NNAL formation in incubation mixtures containing SKF-525A was noted (Fig. 4a) .
Effects of Inhibitors on [5-3 H]NNK Bioactivation: Individual Results. Substantial inhibition of total NNK bioactivation (sum of four ␣-hydroxylation endpoint metabolites) was observed in microsomes from some patients. However, in a number of cases, the presence of either chemical inhibitors or inhibitory antibodies actually increased total ␣-hydroxylation (Table 2) . Also, effects of P450 enzyme-selective chemical inhibitors did not always correlate with effects of specific P450 antibodies (Table 2) .
Nonselective P450 inhibitors. CO lowered total [5-3 H]NNK ␣-hydroxylation in four of five patients' microsomes, by 6.3 to 53% (Table  2) . SKF-525A decreased total ␣-hydroxylation in lung microsomes from three of five patients (6HM, 8HM, and 8JM, all of whom were high bioactivators), with inhibition ranging from 38 to 47% (Table 2) . Additionally, at 1.0 mM, ABT, another nonselective P450 inhibitor, decreased total ␣-hydroxylation in all of five patients' microsomes by 21 to 56%, with the greatest inhibition occurring in tissues from high bioactivators ( Table 2) . Substantial inhibition was observed with 5.0 mM ABT in microsomes from all patients.
Selective P450 inhibitors. Use of selective P450 enzyme inhibitors revealed different patterns of enzyme contributions to NNK bioactivation for different individuals. For patients 6HM and 8JM, both high bioactivators, results suggested considerable CYP2A6 contribution to total ␣-hydroxylation ( played a role in NNK bioactivation in patient 6HM since inhibitory CYP3A4/3A5 antibody and the CYP3A inhibitor TAO also decreased total ␣-hydroxylation. For patient 8HM, another high bioactivator, results suggested contributions particularly of CYP2B6, but also of CYP2A6 and CYP2E1, to NNK total bioactivation (Table 2) . For most of the low bioactivators, no clear-cut patterns with either selective inhibitory antibodies or chemical inhibitors were observed, except that in microsomes from patient 9JM, CYP2A6 appeared to play an important role (Table 2) .
When metabolism of NNK to specific metabolites was examined, levels of inhibition varied between patients and metabolites, and tended to be complementary when both immunoinhibition and chemical inhibition were compared in microsomes from the same individual (data not shown). However, effects of inhibitors did not consistently reveal that formation of any specific metabolite could be attributed to a specific P450 enzyme.
Non-P450 inhibitors. Notable inhibition of total NNK ␣-hydroxylation (i.e., Ͼ20%) by NDGA was observed in three patients' microsomes (8HM, 7JM, and 9JM), with the greatest inhibition occurring in microsomes from patient 7JM, in which inhibitory treatments did not reveal contributions by specific P450 enzymes (Table 2) . Only one patient's microsomes (9JM) demonstrated appreciable inhibition of total ␣-hydroxylation by INDO (i.e., 20%).
Effects of Inhibitors on Total N-Oxidation of [5-3 H]NNK:
Individual Results. Total microsomal N-oxidation (sum of NNK-Noxide and NNAL-N-oxide) showed considerable variability between individual patients ( Fig. 2c; Table 3 ).
Nonselective P450 inhibitors. In three of five patients' microsomes, CO decreased total N-oxidation by 13 to 96%, and the nonselective P450 inhibitors SKF-525A and ABT (1.0 mM) inhibited total Noxidation in four of five patients' microsomes by 36 to 88% and 7.3 to 73%, respectively (Table 3) . Substantial inhibition was observed with 5.0 mM ABT in all microsomes containing detectable N-oxidation products in control incubates.
Selective P450 inhibitors. Although total N-oxide production was highly variable, both enzyme-selective antibody inhibition and chemical inhibition suggested patterns of enzyme-specific contributions. In patient 8HM, the individual whose microsomes formed the highest amounts of N-oxide metabolites, CYP2A6, CYP2B6, and CYP2E1 appeared to be important contributors (Table 3) . For patient 3JM, a relatively low producer of N-oxides, both CYP2A6 and CYP2B6 were implicated (Table 3) . For patients 8JM and 9JM, CYP2A6 appeared to make a significant contribution. For patients 6HM, 7JM, and 8JM, antibodies and chemical inhibitors did not point to clear-cut roles for specific P450 enzymes (Table 3) . As in the case of ␣-hydroxylation, in a number of incubations N-oxidation activities in the presence of either chemical inhibitors or inhibitory antibodies were unexpectedly increased compared with control. Most notable was patient 5JM, an individual in whose microsomes N-oxidation was nondetectable in control incubates (Table 3) . Additionally, effects of enzyme-selective chemical inhibitors of total N-oxide production did not always agree or correlate with effects of antibodies for the same enzyme (i.e., CYP2B6).
Non-P450 inhibitors. Total N-oxide formation was inhibited by 15% or greater in microsomal incubations from five of seven patients' microsomes in the presence of NDGA, and four of seven in the presence of INDO (Table 3) .
Discussion
Despite recognition that NNK is a potent carcinogen in tobacco smoke and may be responsible for the increasing incidence of human pulmonary adenocarcinoma (Hoffmann et al., 1996) , characterization of its biotransformation in human lung remains incomplete. In earlier studies, conclusions regarding the contribution of various biotransformation enzymes to NNK metabolism were based on results from only four individuals in total (Smith et al., 1992 . The principal aim of the present study was to provide a more thorough examination of the contributions of various biotransformation enzymes, particularly P450s, to NNK metabolism in human lung.
Consistent with previous reports (Castonguay et al., 1983; Smith et al., 1992 and our findings in isolated intact lung cells (Smith et , 1999) , carbonyl reduction of NNK to NNAL was the major pathway for NNK metabolism in microsomes from all seven individuals, and total bioactivation (sum of four ␣-hydroxylation endpoint metabolites) represented less than 1% of the initial amount of NNK in the system. Despite the fact that formation of both ␣-hydroxylation and N-oxidation metabolites occurred at very low rates, the enzymatic nature of metabolite production was confirmed by heat lability, NADPH dependence, and inhibition of their production, particularly by ABT.
For most patients, the overall balance between ␣-hydroxylation (bioactivation) and N-oxidation (detoxication) favored bioactivation. Patterns of microsomal metabolite formation pointed out differences in activity of different NNK biotransforming enzymes between patients. Keto acid was the major ␣-carbon hydroxylation metabolite in human lung microsomes, reflecting potential formation of methylating species in smokers' lungs.
NADPH dependence, coupled with pronounced and consistent inhibition of NNK ␣-hydroxylation and N-oxidation by ABT, suggests P450 contributions to NNK metabolism in all patients. In high bioactivators, effects of CO and other inhibitors also support the importance of P450s to NNK bioactivation and detoxication. The inconsistency with which CO and SKF-525A caused inhibition relative to ABT is probably related to the particularly high efficacy of ABT for P450 inhibition in lung microsomes. Indeed, Mathews and Bend (1986) demonstrated complete inhibition of P450 activity in rabbit pulmonary microsomes incubated with 10 mM ABT. In the low human bioactivators, levels of P450 enzymes may have been too low to observe consistent effects with other inhibitors. Alternatively, Kim et al. (1997) reported inhibition of horseradish peroxidase-catalyzed benzo[a]pyrene bioactivation by ABT. Thus, it is conceivable that ABT inhibits non-P450 enzymes that also contribute to human pulmonary NNK biotransformation.
Our results indicate contributions of multiple P450 enzymes to NNK metabolism in human lung microsomes, and these contributions vary between individuals. Results from incubations in the presence of 8-MS or CYP2A6 inhibitory antibody suggest that CYP2A6 is involved in NNK bioactivation in pulmonary microsomes from a number of people, including high and low bioactivators. However, the recently cloned human P450, CYP2A13, cannot be ruled out as a contributor to this activity, since CYP2A6 and CYP2A13 are closely related and antibodies to CYP2A6 recognize both CYP2A6 and CYP2A13 (Su et al., 2000) . CYP2A13 mRNA is expressed in human lung; the corresponding protein has catalytic activity toward a number of CYP2A6 substrates and is more active than CYP2A6 in NNK bioactivation. The apparent importance of CYP2A6/13 is consistent with the findings of , who suggested that NNK bioactivation was catalyzed by CYP2A6 or an immunochemically related P450 in human lung microsomes from three individuals.
Substantial involvement of CYP2B6 in NNK bioactivation in one individual's pulmonary microsomes (patient 8HM) was consistent with the ability of recombinant CYP2B6 to activate NNK to mutagenic species (Smith et al., 1992; Code et al., 1997) , and with immunoreactivity for CYP2B6 being detectable at varying levels in human lung (Mace et al., 1998; Gervot et al., 1999) .
Results with an inhibitory CYP2E1 antibody suggested a role for CYP2E1 in pulmonary NNK bioactivation in some patients' microsomes. Smith et al. (1992) suggested no involvement of CYP2E1 in NNK metabolism in human lung. However, that conclusion was apparently based on results from only one subject, and CYP2E1-catalyzed biotransformation of another nitrosamine, N-nitrosodimethylamine, has been demonstrated at variable levels in human lung microsomes (Botto et al., 1994) . Chemical inhibition studies to corroborate our immunoinhibition results were not performed due to lack of availability of an adequately selective chemical inhibitor. Thus, CYP2E1 contributions to human pulmonary NNK bioactivation warrant further investigation.
Results from incubations with TAO and inhibitory antibodies to CYP3A4/3A5 suggested a minor role for CYP3A4 and/or CYP3A5 in NNK bioactivation in human lung microsomes from only one individual (6HM). CYP3A5 was probably responsible for NNK bioactivation, since it is the major CYP3A enzyme expressed in the lung, with only 20% of individuals expressing CYP3A4 (Anttila et al., 1997) . Also, CYP3A5-mediated NNK ␣-hydroxylation has been demonstrated (Smith et al., 1992) .
The limited effects of INDO on NNK bioactivation may have been due to either inhibition of microsomal PHS-catalyzed ␣-hydroxylation or, possibly, to inhibition of P450s involved in NNK bioactivation. INDO is metabolized primarily by CYP2C9 in human liver microsomes, with minor contributions of CYP2C19, CYP1A2, and CYP2D6 (Nakajima et al., 1998) . To our knowledge, CYP2C8 is the only CYP2C class enzyme expressed in human lung (Nakajima et al., 1994) . Thus, inhibition of CYP2C8 by INDO is plausible in human lung microsomes. CYP2C8 has been implicated in the N-oxidation of NNK (Smith et al., 1992) , which may account for the more pronounced inhibition of total N-oxidation versus total bioactivation in incubations in the presence of INDO.
In the presence of an NADPH-generating system, NDGA inhibited NNK total bioactivation and total N-oxidation in a number of patients' microsomes. Interestingly, the greatest inhibition of bioactivation occurred in microsomes from an individual with apparently limited P450 involvement (Patient 7JM). Although NDGA has antioxidant properties and may inhibit some P450s (Agarwal et al., 1991) , the concentration employed was selected to minimize these effects. However, since LOXs are cytosolic and we have found that human lung LOX cannot bioactivate NNK (Bedard et al., 2002) , the observed inhibition was likely occurring as a result of actions on P450s or other microsomal peroxidases.
Our observation of apparent CYP2A6/13 catalysis of NNK Noxidation was unexpected, since NNK N-oxidation by recombinant CYP2A6 and CYP2A13 was not observed (Smith et al., 1992; Su et al., 2000) . CYP2B6 also appeared to contribute to N-oxidation, whereas involvement of CYP3A4 and/or CYP3A5 in NNK N-oxidation in human lung microsomes remains questionable, since results from CYP3A4/5 inhibitory antibody and TAO did not correlate.
In some microsomal incubations containing either chemical inhibitors or inhibitory antibodies, we observed increased levels of NNK bioactivation and N-oxidation. Large increases in a certain pathway could suggest inhibitor-mediated stimulation of enzyme systems involved in NNK pulmonary biotransformation, and some P450-selective chemical inhibitors activate enzymes other than the P450 target for inhibition (Ueng et al., 1997; Ludwig et al., 1999) . Although paradoxical stimulation of biotransformation can occur with SKF-525A in intact lung cells (Donnelly et al., 1996; Smith et al., 1999) , to our knowledge, this phenomenon has not been reported for the other inhibitors used in this study; also, similar effects are not likely to be observed for inhibitory antibodies. Diversion of substrate from a metabolic pathway that is sensitive to inhibition to one that is not is an unlikely explanation, since the amount of NNK present was far in excess of the amount that would be made available by inhibition of a competing metabolic pathway. Nonuniform constitution of human lung microsomes between incubates may contribute to apparent stimulation by inhibitors. Human lung microsomes can be contaminated by particulate matter such as carbon or tar, accumulated from years of cigarette smoking, which might affect how NNK biotransformation activities are expressed in different incubates. The fact that apparent stimulation by inhibitors occurred almost exclusively in microsomes with low control activities supports this explanation.
The consistent increase in NNAL formation in the presence of 5.0 mM ABT, which averaged ϳ18%, could not be accounted for by increased NNK availability due to inhibition by NNK of ␣-hydroxylation and N-oxidation, and suggests that ABT stimulates microsomal 11␤-hydroxysteroid dehydrogenase (11␤-HSD), the carbonyl reductase responsible for the majority of NNAL formation in human lung (Maser et al., 2000) . Although not statistically significant (P ϭ 0.102), the trend toward decreased NNAL formation in human lung microsomes with 1.0 mM SKF-525A (Fig. 4a) was consistent with sensitivity of 11␤-HSD and/or other carbonyl reductases to SKF-525A (Smith et al., 1999) .
Interindividual variability in NNK biotransformation could potentially be attributed to factors including therapeutic intervention prior to surgery and occupational exposure to biotransformation enzyme inducers and inhibitors. However, no associations between drug treatments and microsomal NNK biotransformation were apparent. We also saw no evidence of smoking status or sex-related differences in microsomal NNK metabolism.
CYP2A6 and CYP2A13 are polymorphic, with high and low activity-variant alleles. Despite the apparent importance of CYP2A6/13 in NNK metabolism in human lung microsomes, the interindividual differences observed in NNK metabolism are unlikely to be attributable to the presence of identified mutant CYP2A6 alleles or 1140 SMITH ET AL.
at ASPET Journals on June 23, 2017 dmd.aspetjournals.org CYP2A13 alleles because the combined frequency of alleles in white populations conferring poor metabolizer phenotypes is less than 3.5% and 2.0%, respectively (Raunio et al., 2001; Zhang et al., 2002) . Nonetheless, the observation of high and low NNK bioactivators is consistent with the proposal of Castonguay et al. (1983) of the existence of a subset of individuals with high NNK bioactivation and, hence, elevated susceptibility to NNK-induced carcinogenesis. Elucidation of the biological processes differentiating these individuals will require further study.
In conclusion, results from the present study indicate that several P450 isozymes contribute to NNK biotransformation in microsomes prepared from human peripheral lung. It is likely that the relative contributions of these enzymes vary between individuals. CYP2A6 and/or CYP2A13 appear to play a significant role in NNK oxidation in lungs of many humans. Other P450 isozymes including CYP2B6, CYP2E1, and CYP3A5 appear to play a role as well, but not in all humans.
